168 related articles for article (PubMed ID: 36607583)
21. Evinacumab to treat hypercholesterolemia.
Engler C; Ebenbichler C
Drugs Today (Barc); 2021 Oct; 57(10):607-619. PubMed ID: 34713869
[TBL] [Abstract][Full Text] [Related]
22. A novel fully human anti-NT-ANGPTL3 antibody from phage display library exhibits potent ApoB, TG, and LDL-C lowering activities in hyperlipidemia mice.
Zhang P; Wang K; Hu T; Xu M; You X; Chen M; Tang X; Hu H; Jiang Y; Zhao W; Tan S
FASEB J; 2024 Jan; 38(1):e23399. PubMed ID: 38174870
[TBL] [Abstract][Full Text] [Related]
23. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
[TBL] [Abstract][Full Text] [Related]
24. Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside.
Ling P; Zheng X; Luo S; Ge J; Xu S; Weng J
Diabetes Obes Metab; 2021 Sep; 23(9):2020-2034. PubMed ID: 34047441
[TBL] [Abstract][Full Text] [Related]
25. Evinacumab for Homozygous Familial Hypercholesterolemia.
Raal FJ; Rosenson RS; Reeskamp LF; Hovingh GK; Kastelein JJP; Rubba P; Ali S; Banerjee P; Chan KC; Gipe DA; Khilla N; Pordy R; Weinreich DM; Yancopoulos GD; Zhang Y; Gaudet D;
N Engl J Med; 2020 Aug; 383(8):711-720. PubMed ID: 32813947
[TBL] [Abstract][Full Text] [Related]
26. A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease.
Hu X; Fan J; Ma Q; Han L; Cao Z; Xu C; Luan J; Jing G; Nan Y; Wu T; Zhang Y; Wang H; Zhang Y; Ju D
J Nanobiotechnology; 2022 May; 20(1):237. PubMed ID: 35590366
[TBL] [Abstract][Full Text] [Related]
27. The Lipid-Modulating Effect of Tangeretin on the Inhibition of Angiopoietin-like 3 (ANGPTL3) Gene Expression through Regulation of LXRα Activation in Hepatic Cells.
Chen PY; Chao TY; Hsu HJ; Wang CY; Lin CY; Gao WY; Wu MJ; Yen JH
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576019
[TBL] [Abstract][Full Text] [Related]
28. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
Dewey FE; Gusarova V; Dunbar RL; O'Dushlaine C; Schurmann C; Gottesman O; McCarthy S; Van Hout CV; Bruse S; Dansky HM; Leader JB; Murray MF; Ritchie MD; Kirchner HL; Habegger L; Lopez A; Penn J; Zhao A; Shao W; Stahl N; Murphy AJ; Hamon S; Bouzelmat A; Zhang R; Shumel B; Pordy R; Gipe D; Herman GA; Sheu WHH; Lee IT; Liang KW; Guo X; Rotter JI; Chen YI; Kraus WE; Shah SH; Damrauer S; Small A; Rader DJ; Wulff AB; Nordestgaard BG; Tybjærg-Hansen A; van den Hoek AM; Princen HMG; Ledbetter DH; Carey DJ; Overton JD; Reid JG; Sasiela WJ; Banerjee P; Shuldiner AR; Borecki IB; Teslovich TM; Yancopoulos GD; Mellis SJ; Gromada J; Baras A
N Engl J Med; 2017 Jul; 377(3):211-221. PubMed ID: 28538136
[TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis.
Minicocci I; Santini S; Cantisani V; Stitziel N; Kathiresan S; Arroyo JA; Martí G; Pisciotta L; Noto D; Cefalù AB; Maranghi M; Labbadia G; Pigna G; Pannozzo F; Ceci F; Ciociola E; Bertolini S; Calandra S; Tarugi P; Averna M; Arca M
J Lipid Res; 2013 Dec; 54(12):3481-90. PubMed ID: 24058201
[TBL] [Abstract][Full Text] [Related]
30. New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.
Su X; Peng DQ
Lipids Health Dis; 2018 Jan; 17(1):12. PubMed ID: 29334984
[TBL] [Abstract][Full Text] [Related]
31. ANGPTL3 as therapeutic target.
Kersten S
Curr Opin Lipidol; 2021 Dec; 32(6):335-341. PubMed ID: 34581310
[TBL] [Abstract][Full Text] [Related]
32. Angiopoietin-like 3 regulates hepatocyte proliferation and lipid metabolism in zebrafish.
Lee SH; So JH; Kim HT; Choi JH; Lee MS; Choi SY; Kim CH; Kim MJ
Biochem Biophys Res Commun; 2014 Apr; 446(4):1237-42. PubMed ID: 24685482
[TBL] [Abstract][Full Text] [Related]
33. Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia.
Sosnowska B; Adach W; Surma S; Rosenson RS; Banach M
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614969
[TBL] [Abstract][Full Text] [Related]
34. Genetically determined deficiency of ANGPTL3 does not alter HDL ability to preserve endothelial homeostasis.
Ossoli A; Minicocci I; Turri M; Di Costanzo A; D'Erasmo L; Bini S; Montavoci L; Veglia F; Calabresi L; Arca M
Biochim Biophys Acta Mol Cell Biol Lipids; 2023 Mar; 1868(3):159263. PubMed ID: 36521735
[TBL] [Abstract][Full Text] [Related]
35. The role of ANGPTL3 in controlling lipoprotein metabolism.
Tikka A; Jauhiainen M
Endocrine; 2016 May; 52(2):187-93. PubMed ID: 26754661
[TBL] [Abstract][Full Text] [Related]
36. Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3.
Watts GF; Raal FJ; Chan DC
Future Cardiol; 2022 Feb; 18(2):143-153. PubMed ID: 34651521
[TBL] [Abstract][Full Text] [Related]
37. Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects.
Lupo MG; Ferri N
J Cardiovasc Dev Dis; 2018 Jul; 5(3):. PubMed ID: 30011918
[TBL] [Abstract][Full Text] [Related]
38. Familial combined hypolipidemia: angiopoietin-like protein-3 deficiency.
Arca M; D'Erasmo L; Minicocci I
Curr Opin Lipidol; 2020 Apr; 31(2):41-48. PubMed ID: 32022755
[TBL] [Abstract][Full Text] [Related]
39. Angiopoietin-like 3 inhibition and the liver: less is more?
Oostveen RF; Hovingh GK; Stroes ESG
Curr Opin Lipidol; 2023 Dec; 34(6):267-271. PubMed ID: 37820081
[TBL] [Abstract][Full Text] [Related]
40. ANGPTL3 Mutations in Unrelated Chinese Han Patients with Familial Hypercholesterolemia.
Yang Y; Yang S; Jiao X; Li J; Zhu M; Wang L; Qin Y
Curr Pharm Des; 2019; 25(2):190-200. PubMed ID: 30827231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
